ABCB1, ABCG2, and CES1 are Key Determinants of the Pharmacokinetics of KRASG12C Inhibitor Divarasib
Divarasib is a selective KRASG12C inhibitor currently in phase 3 trials for treatment of NSCLC. Drug transporters and metabolic enzymes can markedly influence oral drug disposition. We therefore examined whether the efflux transporters ABCB1 and ABCG2, the influx transporter OATP1, and the enzymes CYP3A and CES1 affe...